Abstract Diabetes mellitus may affect bone turnover in a number of ways, thus leading to impaired bone quality and a consequent increase in fracture risk. These factors are summarised in this commentary.
1. Low-grade inflammation mainly linked to obesity affecting turnover in the skeleton [1] . This would predominantly be expected to be a factor in type 2 diabetes. It would by nature lead to a low turnover state in the bones, which is what is seen in diabetes [2, 3] . 2. An altered relationship between the beta cells and bone [4] , as osteocalcin is involved in bone turnover but may also affect the beta cells [5] . If bone turnover is low, osteocalcin levels will decrease, and this may in theory further impair insulin secretion from the beta cells.
3.
Decreased bone turnover resulting from decreased osteoclastic resorption in bone with glycated collagen [2, 3] . Because of the coupling between osteoclasts and osteoblasts, bone turnover would decrease. 4. Altered glycation of collagen and thus impaired biomechanical competence [6] . An increase in fractures stemming from this mechanism would not necessarily be reflected in changes in areal bone mineral density (BMD) determined by dual-energy X-ray absorptiometry (DXA) or other scanning techniques relying on measurements of calcium content of the bones. 5. Lack of the anabolic effects of insulin, which would be present in type 1 diabetes, and less so in type 2 diabetes, where insulin levels may be increased. However, altered levels of IGF1 may also play a role [7] . 6. Negative calcium balance brought about by hyperglycaemia through increased urinary calcium excretion [8] and altered intestinal calcium absorption [9] . 7. Alterations in vitamin D metabolism [10] -in particular in patients with renal disease. 8. Functional hypoparathyroidism [11] . This may be a less significant factor, as, in theory, hypoparathyroidism should lead to increased [12] and not decreased BMD. 9. Drug-specific effects, such as negative effects of peroxisome proliferator-activated receptor γ agonists [13] , but also potential effects of other drugs, such as insulin or the oral glucose-lowering drugs.
Besides these mechanisms, which are linked to bone biomechanical competence, increased risk of falls (for example, from peripheral neuropathy, impaired vision, hypoglycaemia, ischaemic cerebral events) may also play a role. These effects would not be linked to BMD.
To further study these factors it is necessary to determine whether differences exist with age (say, older individuals being more susceptible than younger) or whether sex differences are present. Sex-specific effects could, for example, be related to oestrogen or aromatase activity in women. If older individuals with diabetes were more susceptible, this could point to factors associated with age, such as alterations in bone architecture or the ratio of collagen to hydroxyapatite. Sex-specific differences could point to effects linked to aromatase or to testosterone or oestrogen.
Regarding differences between type 1 diabetes and type 2 diabetes, it has been reported that although an increased risk of fractures may be seen in both conditions [14, 15] , BMD seems to be increased in type 2 diabetes, but this does not confer protection against fractures, as would otherwise be expected. As reported in this issue of Diabetologia, in their study adjusting for BMD, Napoli et al observed an increased risk of fractures, i.e. a risk beyond what can be explained by BMD, among the subgroup of older men with diabetes vs those with normoglycaemia [16] . No clear distinction between type 1 and type 2 diabetes is made in the paper, but the majority of individuals may be expected to have type 2 diabetes. Like Strotmeyer et al [17] , the study by Napoli et al did not find a relationship with impaired fasting glucose. However, Napoli et al did report a relationship with the use of insulin. Insulin may counter hyperglycaemia and thus counter some of the negative effects on bone. However, lack of sufficient intrinsic insulin production may also signal a lack of the potential anabolic effects of insulin, which may not be mimicked by addition of external insulin.
The patients in the study were predominantly elderly type 2 diabetic patients. Insulin treatment in these patients would often be an add-on to, for example, oral glucose-lowering drugs and could signal longstanding and perhaps poorly controlled diabetes. Poorly controlled diabetes needing addition of insulin could thus have led to impaired integrity of the skeleton, as outlined above. Alternative explanations may be increased risk of falls linked to, for example, complications with peripheral neuropathy or affection of the central nervous system linked to, say, ischaemia or stroke.
In conclusion, diabetes may-beyond the well-known acute and late complications-be a risk factor for skeletal frailty in both young and old alike. The possible mechanisms involved span from signalling between the skeleton and beta cell to negative effects on the bone competence by hyperglycaemia.
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